Repurposing Incyclinide for the Treatment of Hospitalized COVID-19 Patients - PROJECT SUMMARY/ABSTRACT
CMTx Biotech is a drug development company working to rescue and repurpose a proprietary clinical-stage drug
candidate, incyclinide (CMT-3 / COL-3), for the treatment of patients infected with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and suffering from Coronavirus disease 2019 (COVID-19). Since late
December 2019, an outbreak of a novel zoonotic coronavirus (SARS-CoV-2 / COVID-19) with clinical
presentations greatly resembling viral pneumonia has claimed the lives of over 418,000 worldwide, including
over 117,000 in the U.S. alone (as of 6/13/2020). COVID-19 is highly contagious, infecting over 7.4 million
patients globally so far, with an average incubation period of 4 days. Frequently reported COVID-19 symptoms
include fever, cough, myalgia or fatigue, and shortness of breath. Approximately 20-30% of hospitalized COVID-
19 patients have required intensive care for respiratory support. COVID-19 can lead to acute lung injury, ARDS,
multiple organ failure and death. Studies have shown that COVID-19 has a mortality rate of up to 4.2%.
Predictors of fatal outcomes include age, the presence of underlying diseases or secondary infection, as well as
elevated inflammatory indicators in the blood, and mortality may be due to virus-activated “cytokine storm
syndrome” or fulminant myocarditis. There is currently no vaccine for COVID-19, and only Remdesivir (Gilead
Sciences) has shown efficacy in a randomized, double-blind, placebo-controlled clinical trial, along with
Emergency Use Authorization from the FDA. Clinical management of COVID-19 patients includes prompt
implementation of recommended infection prevention and control measures, as well as supportive management
of complications, including mechanical ventilation and advanced organ support. CMTx Biotech is working to
repurpose and commercialize incyclinide as a once-daily, orally-administered treatment for hospitalized COVID-
19 patients. Incyclinide is a clinical-stage, non-antibiotic, chemically-modified tetracycline that belongs to a class
of pleiotropic matrix metalloproteinase (MMP) modulators which inhibit pathologically-excessive collagenolysis
and resolve systemic inflammation. Two recent independent studies performed in silico have suggested that
incyclinide may have significant therapeutic benefit in patients with COVID-19. Importantly, the safety of
incyclinide has already been demonstrated in Investigational New Drug (IND)-enabling studies, and incyclinide
has been evaluated in a number of human clinical trials for the treatment of diseases as disparate as AIDS-
related Kaposi's sarcoma, recurrent high-grade gliomas, refractory metastatic cancer, acne, rosacea and
periodontitis. Published pre-clinical efficacy studies have shown that systemic administration of incyclinide
prevents the development of ARDS and septic shock, and improves survival in several chronic insidious onset
animal models of ARDS across several species, including mice, rats, pigs, and sheep. Our long-term goal is to
obtain Emergency Use Authorization (EUA) and regulatory approval from the FDA to market incyclinide for the
safe and effective treatment of COVID-19 patients, as well as to establish a partnership with a pharmaceutical
company in the form of a license or acquisition. We strongly anticipate that incyclinide will inhibit COVID-19
disease progression, mitigate acute lung injury and respiratory distress, reduce the need for intensive care and
intubation, and improve clinical outcomes for COVID-19 patients, including overall survival. Our specific aims
are to design a Phase II clinical study to evaluate the safety and efficacy of incyclinide for the treatment of
hospitalized COVID-19 patients, develop a pre-IND briefing document inclusive of a clinical study synopsis, and
engage the FDA in a pre-IND meeting. Moreover, we intend to prepare key clinical study documents, including
a full clinical study protocol, investigator brochure and informed consent form, along with detailed plans for
statistical analysis, recruitment and retention, and data management, in support of an Investigational New Drug
(IND) submission to the FDA. Successful completion of this clinical trial planning grant will allow us to pursue a
Phase II human clinical study to evaluate a once-daily, orally-administered formulation of incyclinide for the
treatment of hospitalized COVID-19 patients.
